Spoken Alpha
EDSA
Edesa Biotech, Inc.
Overview
Edesa Biotech, Inc is a Healthcare company operating in Biotechnology with a $74.6M market cap.
Most recent reported earnings: Q3 FY2026 (Aug 13, 2026).
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
No earnings calls indexed for EDSA yet
We index calls for roughly 3,000 US-listed companies. If you'd like us to add EDSA, reply to your welcome email and we'll prioritize it.
History
Earnings history
- Q3 FY20262026-08-13EPS— vs $-0.38—Rev— vs ——EODHD
- Q2 FY20262026-05-13EPS$-0.49 vs $-0.26-88.5%Rev$50.9K vs ——EODHD
- Q1 FY20262026-02-12EPS$-0.28 vs $-0.45+37.8%Rev$0 vs ——EODHD
- Q4 FY20252025-12-11EPS$-0.32 vs $-0.56+42.9%Rev$0 vs ——EODHD
- Q3 FY20252025-08-07EPS$-0.25 vs $-0.26+3.9%Rev$0 vs ——EODHD
- Q2 FY20252025-05-13EPS$-0.30 vs $-0.29-3.5%Rev$0 vs ——EODHD
- Q1 FY20252025-02-13EPS$-0.48 vs $-0.31-54.8%Rev$0 vs ——EODHD
- Q4 FY20242024-12-12EPS$-0.29 vs $-0.54+46.3%Rev$0 vs ——EODHD
- Q3 FY20242024-08-08EPS$-0.52 vs $-0.58+10.3%Rev$0 vs ——EODHD
- Q2 FY20242024-05-09EPS$-0.58 vs $-0.69+15.9%Rev$0 vs ——EODHD
- Q1 FY20242024-02-08EPS$-0.54 vs $-1.21+55.4%Rev$0 vs ——EODHD
- Q4 FY20232023-12-14EPS$-0.60 vs $-0.71+15.5%Rev$-1.1M vs ——EODHD
- Q3 FY20232023-08-08EPS$-0.70 vs $-1.21+42.1%Rev$0 vs ——EODHD
- Q2 FY20232023-05-10EPS$-0.84 vs $-1.21+30.6%Rev$0 vs ——EODHD
- Q1 FY20232023-02-09EPS$-0.91 vs $-1.33+31.6%Rev$1.1M vs ——EODHD
- Q4 FY20222022-12-15EPS$-0.02 vs $-0.39+94.9%Rev$0 vs ——EODHD
- Q3 FY20222022-08-11EPS$-2.59 vs $-3.01+14.0%Rev$0 vs ——EODHD
- Q2 FY20222022-05-12EPS$-2.31 vs $-2.57+10.1%Rev$0 vs ——EODHD
- Q1 FY20222022-02-13EPS$-0.33 vs $-0.40+17.5%Rev$0 vs ——EODHD
- Q4 FY20212021-12-27EPS$-2.86 vs $-2.94+2.7%Rev$-3.5M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-08-13 | — | $-0.38 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-05-13 | $-0.49 | $-0.26 | -88.5% | $50.9K | — | — | EODHD |
| Q1 FY2026 | 2026-02-12 | $-0.28 | $-0.45 | +37.8% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-12-11 | $-0.32 | $-0.56 | +42.9% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-08-07 | $-0.25 | $-0.26 | +3.9% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-05-13 | $-0.30 | $-0.29 | -3.5% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-02-13 | $-0.48 | $-0.31 | -54.8% | $0 | — | — | EODHD |
| Q4 FY2024 | 2024-12-12 | $-0.29 | $-0.54 | +46.3% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-08-08 | $-0.52 | $-0.58 | +10.3% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-05-09 | $-0.58 | $-0.69 | +15.9% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-02-08 | $-0.54 | $-1.21 | +55.4% | $0 | — | — | EODHD |
| Q4 FY2023 | 2023-12-14 | $-0.60 | $-0.71 | +15.5% | $-1.1M | — | — | EODHD |
| Q3 FY2023 | 2023-08-08 | $-0.70 | $-1.21 | +42.1% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-05-10 | $-0.84 | $-1.21 | +30.6% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-02-09 | $-0.91 | $-1.33 | +31.6% | $1.1M | — | — | EODHD |
| Q4 FY2022 | 2022-12-15 | $-0.02 | $-0.39 | +94.9% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-08-11 | $-2.59 | $-3.01 | +14.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-05-12 | $-2.31 | $-2.57 | +10.1% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-02-13 | $-0.33 | $-0.40 | +17.5% | $0 | — | — | EODHD |
| Q4 FY2021 | 2021-12-27 | $-2.86 | $-2.94 | +2.7% | $-3.5M | — | — | EODHD |
Source: EODHD. EDSA reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks EDSA's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 80% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.06 | $0.74 | +42.6% | -5.7% | -6.5% |
| Q4 FY2026 | $0.95 | $0.66 | +44.6% | -5.3% | -2.8% |
| Q3 FY2026 | $0.96 | $0.66 | +45.0% | -5.5% | -3.7% |
| Q2 FY2026 | $1.25 | $0.84 | +48.3% | +3.9% | +2.0% |
| Q1 FY2025 | $1.19 | $0.81 | +46.4% | -2.2% | -4.9% |
| Q4 FY2025 | $1.22 | $0.88 | +38.5% | +0.1% | +0.4% |
| Q3 FY2025 | $0.95 | $0.69 | +37.0% | -6.1% | -5.6% |
| Q2 FY2025 | $1.28 | $0.86 | +49.2% | -4.0% | -2.5% |
| Q1 FY2024 | $1.38 | $0.97 | +42.1% | -1.9% | +0.6% |
| Q4 FY2024 | $1.21 | $0.84 | +44.6% | -1.0% | +1.6% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Pardeep NijhawanCEO7 yr 1 mono recorded callsCurrentSample
CEO since 2019 • 20/28 beats (71%) • last call held guidance Q3 FY2026
- Peter J WeilerCFO1 yr 2 mono recorded callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • guidance suspended Q2 FY2026
- Michael J BrooksPresident7 yr 1 mono recorded callsCurrentSample
PRESIDENT since 2019 • 13/28 beats (46%) • last guidance cut Q1 FY2026
- Nijhawan Medicine Professional Corp PardeepCEO2 yr 6 mono recorded callsFormerSample
CEO since 2020 • 12/24 beats (50%) • last guidance cut Q2 FY2026
- Frank R OakesCEO2 yr 2 mono recorded callsFormerSample
CEO since 2017 • 27/36 beats (75%) • last call held guidance Q3 FY2026
- Stephen LemieuxCFO1 mono recorded callsFormerSample
CFO since 2023 • 4/12 beats (33%) • last guidance cut Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for EDSA.
$ curl https://api.spokenalpha.com/v1/companies/EDSAFAQ
Frequently asked about EDSA
Where can I find Edesa Biotech, Inc.'s (EDSA) earnings call transcripts?
Spoken Alpha indexes EDSA's earnings call transcripts at https://spokenalpha.com/companies/EDSA. Each call links to attributed speakers and parsed analyst Q&A. Edesa Biotech, Inc.'s own investor relations page is at https://www.edesabiotech.com/investors/.
What sector is EDSA in?
Edesa Biotech, Inc. (EDSA) operates in the Healthcare sector (Biotechnology industry).